Policy & Regulation
BioArctic commences phase 1 study of ABBV-0805 for Parkinson's disease
14 March 2019 -

BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Wednesday that the first clinical study with ABBV-0805 has started in the US.

Reportedly, biopharmaceutical company AbbVie Inc (NYSE:ABBV) is responsible for the clinical development of ABBV-0805. This phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805.

According to the company, ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. This antibody is being evaluated as a disease modifying treatment for Parkinson's disease.

ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.

BioArctic is focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury.